Shire -4.4% after Vyvanse misses primary endpoints in two phase-3 studies

Shire (SHPG) -4.4% AH after announcing that results from two Phase 3 studies for Vyvanse capsules as an adjunctive treatment for adults with major depressive disorder did not meet the primary efficacy endpoint in either study, and Shire will no longer pursue the clinical development program.

Shire says it we will file later this year with the FDA for a new indication for Vyvanse in binge eating disorder in adults; Vyvanse already is approved for the treatment of ADHD in the U.S., Canada, Australia, Brazil and several European countries.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs